Drug Profile
Herpes simplex glycoprotein vaccine - Takeda
Latest Information Update: 16 Oct 2000
Price :
$50
*
At a glance
- Originator Takeda
- Class Synthetic vaccines; Viral vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Herpes simplex virus infections
Most Recent Events
- 16 Oct 2000 Discontinued-Preclinical for Herpes simplex virus infections in Japan (Unknown route)
- 13 Jun 2000 No-Development-Reported for Herpes simplex virus infections in Japan (Unknown route)
- 16 Apr 1996 New profile